Exenatide, Liraglutide

PreclinicalPeptide

UUniversity of Dundee

Exenatide, Liraglutide is one of 19 small molecule programs targeting Diabetes. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DiabetesCompleted

DiabetesPreclinical

Completed

Competition

Competitive Landscape

22 competitors in Diabetes

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

7 2

Mounjaro

Eli Lilly

Approved

1 3

Singulair

OOrganon and Co

Approved

1 4

Inulin and Sodium Chloride

BBlue Earth Diagnostics

Approved

1 5

Taltz

Eli Lilly

Phase 2

1 6

Berberine

XXijing Hospital of Digestive Diseases

Phase 3

1 7

Myalept

Chiesi Farmaceutici S.p.A.

Phase 2

1 8

NOVOLIN R

Novo Nordisk

Preclinical

1 9

Sodium Benzoate

LLiminal BioSciences Ltd.

Phase 1

1 10

Formoterol Furmarate (20 Μg)

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetes1 trial

DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists

Completed·UUniversity of Dundee·N/A·NCT01575301·411 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Exenatide, Liraglutide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Exenatide, Liraglutide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Exenatide, Liraglutide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Dundee company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Dundee

Exenatide, Liraglutide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetes1 trial

References

Drug Info

Quick Facts

Related News